EVFM Projected Dividend Yield

Com Par $0.0001/Evofem Biosciences Inc ( OTCBB : EVFM )

Evofem Biosciences is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. Co.'s commercial product, Phexxi, is the U.S. Food and Drug Administration (FDA)-approved, hormone-free, woman-controlled, contraceptive gel for women. Co. is evaluating EVO100 for the prevention of urogenital chlamydia and gonorrhea in women. Co.'s investigational candidate for the reduction of recurrent bacterial vaginosis, EVO200 vaginal gel, uses the same proprietary vaginal pH modulator platform as Phexxi. The FDA has designed EVO200 as a Qualified Infectious Disease Product.

20 YEAR PERFORMANCE RESULTS